The Topical Nanodelivery of Vismodegib Enhances Its Skin Penetration and Performance In Vitro While Reducing Its Toxicity In Vivo

Vismodegib is a first-in-class inhibitor for advanced basal cell carcinoma treatment. Its daily oral doses present a high distribution volume and several side effects. We evaluated its skin penetration loaded in diverse nanosystems as potential strategies to reduce side effects and drug quantities....

Descripción completa

Detalles Bibliográficos
Autores principales: Calienni, Maria Natalia, Maza Vega, Daniela, Temprana, C. Facundo, Izquierdo, María Cecilia, Ybarra, David E., Bernabeu, Ezequiel, Moretton, Marcela, Alvira, Fernando C., Chiappetta, Diego, Alonso, Silvia del Valle, Prieto, María Jimena, Montanari, Jorge
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912039/
https://www.ncbi.nlm.nih.gov/pubmed/33535434
http://dx.doi.org/10.3390/pharmaceutics13020186

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7912039/
https://www.ncbi.nlm.nih.gov/pubmed/33535434
http://dx.doi.org/10.3390/pharmaceutics13020186

Ejemplares similares